Ultrahuman introduces cost-effective continuous glucose monitoring for consumers in the United States.

      Ultrahuman has unveiled the debut of M2 Live in the United States, enhancing access to continuous glucose monitoring and metabolic health insights for consumers who do not have diabetes. This new platform incorporates glucose data from Abbott’s Lingo continuous glucose monitor (CGM), enabling users to monitor their metabolic health without the need for a prescription.

      This launch signifies a major advancement for the company, which played a key role in making glucose monitoring popular among wellness-oriented consumers when it launched its first metabolic tracking platform in 2021. With M2 Live, Ultrahuman aims to offer this technology at more affordable rates, with subscriptions starting at $99 per month and individual sensors priced at $129.

      The company indicates that the platform is intended for adults wanting to gain a better understanding of how factors such as food, exercise, stress, and sleep impact their bodies in real-time. It is also open to individuals with prediabetes who wish to enhance their overall metabolic health.

      Combining glucose tracking with AI-driven health insights

      In contrast to conventional glucose monitoring solutions that focus exclusively on blood sugar levels, M2 Live merges glucose data with various health metrics to deliver a more holistic view of wellness.

      The platform integrates information from Abbott’s Lingo biosensor with data collected from the Ultrahuman Ring and the company’s Blood Vision service, which evaluates over 100 blood biomarkers. This enables users to observe glucose trends alongside factors like sleep quality, activity levels, recovery, stress, heart rate variability, and body temperature.

      The experience is powered by Jade AI, Ultrahuman’s real-time biointelligence engine. This system analyzes health data and elucidates the reasons behind fluctuations in glucose levels by linking them to lifestyle elements such as meals, exercise routines, sleep patterns, and recovery habits.

      M2 Live also features various tools aimed at simplifying the understanding of glucose data. These include a daily Metabolic Score ranging from 0 to 100, customized Food Scores that illustrate how particular foods influence glucose levels, real-time spike notifications, workout-oriented Fueling Scores, and access to OGDb, which the company claims is the largest open glucose database worldwide.

      As per Ultrahuman, only one in eight adults in the US is metabolically healthy, which contributes to conditions such as Type 2 diabetes and cardiovascular diseases. The company contends that offering real-time metabolic insights can empower users to make improved health decisions before more serious health issues arise.

      Founded on extensive research and clinical validation

      Ultrahuman is also emphasizing the scientific basis of its platform.

      The company asserts that its Metabolic Score has been clinically validated through a multi-center study published in Nature, highlighting its effectiveness in differentiating between non-diabetic and prediabetic individuals. Additionally, it cites recent partnerships with institutions like Stanford University, Bangor University, La Trobe University, and the Mayo Clinic as part of its extensive research in metabolic health.

      The launch occurs as consumer health technology is advancing rapidly from basic fitness tracking to more comprehensive health monitoring. As over-the-counter continuous glucose monitors become increasingly accessible, platforms like M2 Live are poised to extend metabolic health tracking to a much wider audience.

      Ultrahuman reports that M2 Live will be available in the US via its website in the upcoming weeks. Each Lingo sensor can be worn for up to 14 days, allowing users continuous access to glucose data and personalized health insights throughout the day.